All Seven Standard Safety Guidelines Are Prevention. Nobody Writes the Other Half.
Start small. Don't mix with alcohol. Check your local laws. Buy from a reputable supplier. Use dried material. Have someone with you. Ask a doctor. That's the standard list, and every item on it is about stopping something from happening. Not one tells you what to do once it has. In October 2018 a man in Minnesota misidentified Amanita muscaria var. guessowii as an edible species from his home country, cooked it with turmeric and oil, and ate it with his daughter. Two to three hours later he had altered mental status, vomiting, incontinence and excessive salivation. What saved him wasn't a guideline — it was endotracheal intubation for airway protection and four days of mechanical ventilation (MMWR, CDC, 31 May 2019). He was discharged on day eight. His daughter, who ate less, went home the next day.
What the Standard List Leaves Out
Prevention advice is only half of safety, and it's the half that stops being useful at exactly the moment safety starts to matter. The other half — recognition and response — is standard in every other risk domain. Fire safety doesn't stop at "don't leave the hob on"; it tells you where the extinguisher is and when to get out instead. Allergy guidance doesn't stop at avoidance; it covers the adrenaline pen.
For Amanita, the response half is well documented in the toxicology literature and almost entirely absent from consumer content. What follows is drawn from that literature. None of it is a substitute for emergency services, and none of it is something to attempt as a home treatment — the point is to know what actually happens, what to say, and what not to do.
The First Thing That Matters Is the Airway
The WHO/IPCS monograph's management section opens where emergency clinicians open: "Make a proper assessment of airway, breathing, circulation and neurological status of the patient" (IPCS INCHEM, PIM G026). That ordering isn't ceremonial. In the Minnesota case the life-threatening problem was respiratory, and the intervention was mechanical.
The practical consequence for a non-clinician is narrow but real. Someone heavily sedated and vomiting is at risk of aspirating, and the standard first-aid response — placing an unresponsive but breathing person on their side in the recovery position, and staying with them — exists precisely for that. If breathing is inadequate or they can't be roused, that's an emergency call, not a wait-and-see. This is also the concrete answer to what "have someone present" is actually for, which brings us to the one item on the standard list pointing in the right direction.
"Have Someone Present" Is Right, and Uselessly Vague
Item six is the only guideline that anticipates something going wrong, and it stops at the word "present." A person in the room who doesn't know what they're watching for is decoration.
Give them a job description instead. They should know the species and the approximate amount taken, and when. They should know that the person may fluctuate — the toxicology literature specifically notes patients alternating between excitatory and depressive phases, which is why intensive monitoring is recommended rather than a single assessment (Stoeva-Grigorova et al., Toxins, 2025). Someone who looks settled at hour two is not necessarily settled at hour four. They should know to keep the person off their back if they're vomiting, to not leave them alone, to not let them drive or bathe, and to call rather than manage it themselves if consciousness or breathing changes.
What Not to Do: The Atropine Problem
This one is worth knowing precisely because the species name points the wrong way. Muscarine was named after this mushroom, which leads people — occasionally including well-meaning bystanders — to assume a cholinergic crisis and reach for the classical antidote.
The monograph is unambiguous: "Atropine is not recommended." The 2025 review adds the nuance that atropine can address peripheral muscarinic effects but "does not counteract the central manifestations," so its use requires specific clinical indication rather than reflex. Amanita muscaria contains very little muscarine; the dominant compounds are muscimol and ibotenic acid, acting on GABA-A and glutamate receptors respectively (Michelot & Melendez-Howell, Mycological Research, 2003). We unpack the same family of species confusions — including the liver warning that belongs to a different Amanita entirely — in our piece on who should avoid Amanita muscaria.
There Is No Antidote — Which Changes What "Treatment" Means
Both sources say it plainly. "There is no specific antidote for Amanita muscaria and Amanita pantherina poisoning" (PIM G026); the 2025 review concurs that no specific antidote exists, attributing the difficulty to the combined cholinergic and anticholinergic picture.
So hospital treatment is supportive rather than curative: respiratory and cardiovascular support, correction of fluid and electrolyte derangements, and control of convulsions, for which the monograph states that "sedation with benzodiazepines is required." Activated charcoal appears in both sources but heavily qualified — most effective within an hour of ingestion, and per the monograph "rarely indicated and only in very recent ingestion, while the patient is asymptomatic." That last clause matters: by the time symptoms have appeared, that window has generally closed. It is not a home remedy and not something to improvise.
The Timing Numbers Somebody Will Ask You For
Sources differ slightly, and the honest version is a range rather than a figure. The monograph gives symptom onset at 30 to 90 minutes, lasting usually about 6 hours but potentially persisting 12 to 24 hours. The 2025 review gives onset from 30 minutes to 2–3 hours with a total course around 24 hours and hallucinations up to 8 hours. The Minnesota case had onset at 2–3 hours.
Two practical points fall out of that spread. First, the window is wider than any single number suggests, so "nothing yet, must be fine" is not a safe inference at the 90-minute mark. Second — and this is the failure mode the case reports keep showing — a delayed onset invites redosing, which is how a modest amount becomes a large one. Our summary of what the adverse-event record actually contains covers the severe end of that pattern.
What to Tell Poison Control or the Emergency Department
This is the single most useful thing a prevention list could have included, and it costs nothing to prepare in advance. Clinicians need: the species (say Amanita muscaria, not a brand name), the form and approximate amount, the time of ingestion, anything else taken including alcohol and prescription medication, and the person's medical history. Bring the actual product or packaging if you can, and keep any remaining material rather than discarding it.
Naming the pharmacology helps too — muscimol as a GABA-A agonist, ibotenic acid as a glutamate-receptor agonist — because there's no interaction monograph to look up, which is a problem we set out in full in why nobody can actually screen you for this. Keeping those fields written down before anything happens is exactly the case for treating a record as a safety and traceability document rather than a reflective diary.
Auditing the Original Seven, Briefly
Two hold up well. "Never mix with alcohol" is the best item on the list — combining CNS depressants is the scenario with the most quantified precedent behind it. "Research local laws" is sound and increasingly non-trivial as jurisdictions move, which we track in our piece on who actually decides Amanita's future.
Two are weaker than they sound. "Buy from a reputable supplier" can't be verified by the buyer, because there are no widely recognised testing standards for retail products (Ordak, Frontiers in Pharmacology, 2026) — reputation is not an assay. And "start with the smallest amount" assumes a measurable unit; dried weight isn't one, since drying converts ibotenic acid to muscimol at an uncontrolled rate. The most consequential safety step isn't on the list at all: correct species identification, since the Minnesota case and much of the case literature begins with misidentification, not misdosing. Our identification and safe-use guide covers that properly.
The Bottom Line
A safety list that only tells you how to avoid a problem has nothing to say during one, and the case record suggests that's when the real decisions get made. The response half is short and knowable: airway first, recovery position and don't leave them, call rather than manage, no atropine, no antidote exists so treatment is supportive, and have the species, amount, timing and co-ingestants ready to hand over. Amanita muscaria isn't an approved treatment for any condition and nothing here is medical advice or a substitute for emergency care — if someone is unresponsive, breathing poorly, or seizing, that's an emergency call, immediately.
Keep your local emergency number and poison-control number somewhere you can find them without thinking. In the US that's Poison Control on 1-800-222-1222; elsewhere, look up your national poison centre now rather than during. And if you take sedatives, sleep medication or anti-anxiety medication, speak to a clinician before considering any GABA-A active substance.
Frequently Asked Questions
Is there an antidote for Amanita muscaria poisoning?
No. The WHO/IPCS monograph states there is no specific antidote for Amanita muscaria or Amanita pantherina poisoning, and a 2025 toxicology review agrees. Hospital treatment is supportive — airway and circulatory support, fluid and electrolyte correction, and benzodiazepines to control convulsions.
Should atropine be given?
No — the monograph states directly that atropine is not recommended. Despite the species giving muscarine its name, Amanita muscaria contains very little of it, and the 2025 review notes atropine doesn't counteract the central effects even where peripheral ones are present.
What's the single most important thing a person present should do?
Protect the airway and stay. Standard first aid for an unresponsive but breathing person is the recovery position, on their side, which reduces aspiration risk during vomiting. If breathing is inadequate or the person can't be roused, call emergency services rather than waiting it out.
How long before symptoms appear?
Sources give a range rather than a fixed figure: the WHO/IPCS monograph says 30 to 90 minutes, a 2025 review says 30 minutes to 2–3 hours, and the Minnesota MMWR case had onset at 2–3 hours. Because the window is wide, feeling nothing at 90 minutes doesn't mean nothing is coming — and redosing during that gap is a recurring failure mode.
How long do effects last?
The monograph gives roughly 6 hours typically, potentially persisting 12 to 24 hours. The 2025 review describes a course of around 24 hours with hallucinations up to 8 hours. Toxicology sources also note patients may fluctuate between excitatory and depressive phases, which is why monitoring is continuous rather than a single check.
Does activated charcoal help?
Only in a narrow window, and it's a clinical decision, not a home one. Both sources describe it as most effective within about an hour of ingestion, and the monograph adds that it is rarely indicated and only in very recent ingestion while the patient is still asymptomatic.
What information should I give the emergency department?
Species — say Amanita muscaria rather than a brand name — plus form, approximate amount, time of ingestion, everything else taken including alcohol and prescription medicines, and relevant medical history. Bring the product or packaging and keep any remaining material. Naming the active compounds helps, since there's no interaction monograph for clinicians to consult.
Written by Viktor, Amanita Store. We sell dried Amanita muscaria caps and tincture as wellness and collector items, not as treatments — which is why this page covers what the toxicology literature says happens, not just how to avoid needing it.